Prothrombotic Changes in Hemostatic Parameters and C-reactive Protein in the Elderly with Winter Acute Respiratory Tract Infections

Summary

Mortality rates attributable to cerebrovascular and ischemic heart disease increase among older adults during the winter. Prothrombotic changes in the hemostatic system related to seasonal factors, such as ambient temperature changes, and winter acute respiratory tract infections, may contribute to this excess seasonal mortality. A prospective nested case-control study was conducted to assess the impact of winter acute respiratory tract infections on fibrinogen, factor VII, factor VIIa, D-dimer, prothrombin fragment 1.2, PAI-1, soluble P-selectin and C-reactive protein (CRP) in older adults. The change in laboratory parameters from baseline (fall) to the time of infection in both middle-aged and elderly individuals was compared with matched non-infected controls. In older adult participants with winter acute respiratory tract infections, significant increases occurred in fibrinogen and C-reactive protein, but not in any other markers. The mean fibrinogen increased 1.52 g/L (38%) and the mean CRP increased 37 mg/L (370%) over baseline (both p < 0.001). In a multivariate analysis, both infection and season were associated with the increase in fibrinogen, but only infection was associated with the CRP increase. Old age magnified the increase in CRP but not in fibrinogen. Winter acute respiratory tract infections induce an exaggerated inflammatory response in older adults. The associated increase in fibrinogen, an independent risk factor for ischemic heart disease, may be partly responsible for the excess winter vascular mortality.

Keywords

Respiratory tract infection - aged - stroke - ischemic heart disease - fibrinogen - C-reactive protein - season - hypercoagulability

• References

• 1 Bull GM, Morton J. Relationships of temperature with death rates from all causes and from certain respiratory and arteriosclerotic diseases in different age groups. Age Ageing 1975; 4 (Suppl. 04) 232-46.
• 2 Monto AS, Ullman BM. Acute respiratory illness in an American community. The Tecumseh study. JAMA 1974; 227 (Suppl. 02) 164-9.
• 3 Falsey AR, McCann RM, Hall WJ, Tanner MA, Criddle MM, Formica MA, Irvine CS, Kolassa JE, Barker WH, Treanor JJ. Acute respiratory tract infection in daycare centers for older persons. J Am Geriatr Soc 1995; 43 (Suppl. 01) 30-6.
• 4 Spodick DH, Flessas AP, Johnson MM. Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol 1984; 53 (Suppl. 04) 481-2.
• 5 Syrjanen J, Valtonen VV, Iivanainen M, Kaste M, Huttunen JK. Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. Br Med J (Clin Res Ed) 1988; 296 (6630) 1156-60.
• 6 Alling DW, Blackwelder WC, Stuart-Harris CH. A study of excess mortality during influenza epidemics in the United States, 1968-1976. Am J Epidemiol 1981; 113 (Suppl. 01) 30-43.
• 7 Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258 (Suppl. 09) 1183-6.
• 8 Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes [published erratum appears in BMJ 1991 Oct 19; 303 (6808): 968]. BMJ 1991; 303 (6803) 605-9.
• 9 Hager K, Platt D. Fibrin degradation product concentrations (D-dimers) in the course of ageing. Gerontology 1995; 41 (Suppl. 03) 159-65.
• 10 Stout RW, Crawford V. Seasonal variations in fibrinogen concentrations among elderly people [see comments]. Lancet 1991; 338 (8758) 9-13.
• 11 Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW. Seasonal variations of plasma fibrinogen and factor VII activity in older adults: winter infections and death from cardiovascular disease [see comments]. Lancet 1994; 343 (8895) 435-9.
• 12 Cushman M, Lemaitre RN, Kuller LH, Psaty BM, Macy EM, Sharieff AR, Tracy RP. Fibrinolytic activation markers predict myocardial infarction in older adults. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19 (Suppl. 03) 493-8.
• 13 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study [see comments]. Lancet 1986; 2 (8506) 533-7.
• 14 Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction [see comments]. Lancet 1993; 341 (8854) 1165-8.
• 15 Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D- dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90 (Suppl. 05) 2236-40.
• 16 Hamsten A, de Faire U, Walldius G, Dahlen G, Szamos A, Landou C, Blowback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2 (8549) 3-9.
• 17 Frohlich M, Sund M, Russ S, Hoffmeister A, Fischer HG, Hombach V, Koenig W. Seasonal variations of rheological and hemostatic parameters and acute- phase reactants in young, healthy subjects. Arterioscler Thromb Vasc Biol 1997; 17 (Suppl. 11) 2692-7.
• 18 Stout RW, Crawford VL, McDermott MJ, Rocks MJ, Morris TC. Seasonal changes in haemostatic factors in young and elderly subjects. Age Ageing 1996; 25 (Suppl. 03) 256-8.
• 19 Falsy AR, Walsh EE. Humoval immunity to respiratory virus infection in the elderly. Journal of Medical Virology. 1992; 36: 39-43.
• 20 Clauss A. Gerinnungsphysiologische schnellmethode zur bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
• 21 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81 (Suppl. 03) 734-44.
• 22 Nas Ki MC, Shafer JA. A kinetic model for the -thrombin-catalyzed conversion of plasma levels of fibrinogen to fibrin in the presence of anti-thrombin III. J Biol Chem 1992; 266: 13003-10.
• 23 Doutremepvich F, Aguejouf O, Belougne-Malfatt E, Doutremepvich C. Fibrinogen as a factor of thrombosis: experimental study. Thromb Res 1998; 90: 57-64.
• 24 Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen C-reactive protein, albumin or leukocyte count with coronary heart disease: a meta-analysis of prospective studies. JAMA 1998; 279 (Suppl. 18) 1477-82.
• 25 Williams JE, Cypher JJ, Mosesson MW. Evidence that production of platelet fibrinogen is synchronous with platelet production in the turpentine-induced acute phase response. J Lab Clin Med 1985; 106 (Suppl. 03) 343-8.
• 26 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation [published erratum appears in N Engl J Med 1999 Apr 29; 340 (17): 1376]. N Engl J Med 1999; 340: 448-54.
• 27 Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poli V. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994; 180: 1243-50.
• 28 Zheng H, Fletcher D, Kozak W, Jiang M, Hofmann KJ, Conn CA, Soszynski D, Grabiec C, Trumbauer ME, Shaw A. et al. Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity 1995; 3: 9-19.
• 29 Wang L, Rayanade RJ, Garcia D, Patel K, Pan H, Sehgal PB. Modulation of interleukin-6-induced plasma protein secretion in hepatoma cells by p53 species. J Biol Chem 1995; 270: 23159-65.
• 30 Stirling D, Hannant WA, Ludlam CA. Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6. Thromb Haemost 1998; 79: 74-8.
• 31 Seki T, Healy AM, Fletcher DS, Noguchi T, Gelehrter TD. IL-1beta mediates induction of hepatic type 1 plasminogen activator inhibitor in response to local tissue injury. Am J Physiol 1999; 277: G801-9.
• 32 Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 1998; 101: 643-9.
• 33 Zhu Z, Tang W, Ray A, Wu Y, Einarsson O, Landry M, Gwaltney J, Elias J. Rhinovirus stimulation of interleukin-6 in vivo and in vitro. Evidence for nuclear factor kappa B-dependent transcriptional activation. Jour Clin Invest 1996; 97: 421-30.
• 34 Stouthard JM, Levi M, Hack CE, Veenhof CH, Romijn HA, Sauerwein HP, van der Poll T. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76: 738-42.
• 35 Oleksowicz L, Puszkin E, Mrowiec Z, Isaacs R, Dutcher JP. Alterations in platelet function in patients receiving interleukin-6 as cytokine therapy. Cancer Invest 1996; 14: 307-16.
• 36 Peng J, Friese P, Wolf RF, Harrison P, Downs T, Lok S, Dale GL, Burstein SA. Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs. Blood 1996; 87: 4158-63.
• 37 Zhang D, Sun M, Samols D, Kushner I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem 1996; 271: 9503-9.
• 38 Ruuskanen O, Putto A, Sarkkinen H, Meurman O, Irjala K. C-reactive protein in respiratory virus infections. J Pediatr 1985; 107: 97-100.
• 39 Rink L, Cakman I, Kirchner H. Altered cytokine production in the elderly. Mech Ageing Dev 1998; 102: 199-209.
• 40 Ballou SP, Lozanski FB, Hodder S. et al. Quantitative and qualitative alterations of acute-phase proteins in healthy elderly persons. Age Ageing 1996; 25 (Suppl. 03) 224-30.
• 41 Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hemmekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published erratum appears in N Engl J Med 1997 Jul 31; 337 (5): 356] [see comments]. N Engl J Med 1997; 336: 973-9.
• 42 Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
• 43 DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
• 44 Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 1985; 57 2-3 163-77.
• 45 Lagrand WK, Niessen HW, Wolbink GJ. et al. CRP colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95 (Suppl. 01) 97-103.
• 46 O’Donnell J. et al. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000; 83 (Suppl. 01) p. 10-3.
• 47 Kyrle PA. et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl Med 2000; 343 (Suppl. 07) p. 457-62.
• 48 Meijers JC. et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342 (Suppl. 10) p. 696-701.
• 49 Stirling D, Hannant WA, Ludlam CA. Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6. Thromb Haemost 1998; 79 (Suppl. 01) p. 74-8.
• 50 Saito I. et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000; 133 (Suppl. 02) 81-91.